State of New Jersey Common Pension Fund D Buys 9,547 Shares of Progyny, Inc. (NASDAQ:PGNY)

State of New Jersey Common Pension Fund D grew its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 14.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 73,864 shares of the company’s stock after purchasing an additional 9,547 shares during the quarter. State of New Jersey Common Pension Fund D owned about 0.08% of Progyny worth $2,746,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. RiverPark Advisors LLC lifted its stake in Progyny by 54.0% in the fourth quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock valued at $40,000 after buying an additional 374 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Progyny during the third quarter valued at about $53,000. Parkside Financial Bank & Trust raised its holdings in shares of Progyny by 9.3% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company’s stock valued at $115,000 after purchasing an additional 264 shares during the period. CWM LLC boosted its position in shares of Progyny by 16.1% during the 3rd quarter. CWM LLC now owns 3,490 shares of the company’s stock worth $119,000 after purchasing an additional 483 shares in the last quarter. Finally, Cetera Trust Company N.A bought a new stake in Progyny during the 4th quarter valued at $183,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Insider Buying and Selling at Progyny

In related news, Chairman David J. Schlanger sold 20,000 shares of Progyny stock in a transaction on Monday, February 5th. The shares were sold at an average price of $38.50, for a total value of $770,000.00. Following the transaction, the chairman now owns 86,312 shares in the company, valued at approximately $3,323,012. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, President Michael E. Sturmer sold 2,260 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $40.00, for a total value of $90,400.00. Following the transaction, the president now owns 158,532 shares in the company, valued at $6,341,280. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman David J. Schlanger sold 20,000 shares of the company’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $38.50, for a total transaction of $770,000.00. Following the sale, the chairman now owns 86,312 shares of the company’s stock, valued at $3,323,012. The disclosure for this sale can be found here. Insiders have sold 120,515 shares of company stock worth $4,570,131 over the last ninety days. Insiders own 12.30% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on PGNY shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $48.00 price objective on shares of Progyny in a research note on Wednesday, February 28th. Leerink Partnrs reissued an “outperform” rating on shares of Progyny in a report on Monday, February 26th. Barclays started coverage on shares of Progyny in a research report on Wednesday, January 3rd. They set an “overweight” rating and a $48.00 price target for the company. KeyCorp reduced their target price on shares of Progyny from $45.00 to $43.00 and set an “overweight” rating for the company in a research report on Wednesday, February 28th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $46.00 price target on shares of Progyny in a report on Wednesday, April 17th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $48.30.

Progyny Stock Performance

Progyny stock opened at $32.54 on Tuesday. The firm’s fifty day moving average price is $35.68 and its 200-day moving average price is $35.64. Progyny, Inc. has a fifty-two week low of $29.44 and a fifty-two week high of $44.95. The stock has a market cap of $3.13 billion, a P/E ratio of 52.48, a PEG ratio of 1.32 and a beta of 1.48.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The firm had revenue of $269.94 million for the quarter, compared to analysts’ expectations of $274.08 million. During the same quarter last year, the company posted $0.03 EPS. The business’s quarterly revenue was up 26.0% on a year-over-year basis. Sell-side analysts predict that Progyny, Inc. will post 0.7 earnings per share for the current year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.